Literature DB >> 1979813

(+)-N-methyl-1-(1,3-benzodioxol-5-yl)-2-butanamine as a discriminative stimulus in studies of 3,4-methylenedioxy-methamphetamine-like behavioral activity.

R Oberlender1, D E Nichols.   

Abstract

The stimulus properties of 3,4-methylenedioxymethamphetamine (MDMA)-like compounds were studied in rats trained to discriminate saline from (+)-N-methyl-1-(1,3-benzodioxol-5-yl)-2-butanamine [(+)-MBDB] hydrochloride (7.18 mumol/kg; 1.75 mg/kg), the alpha-ethyl homolog of MDMA. In previous experiments with (+)-MBDB as a test drug, complete substitution was observed for MDMA but not for (+)-lysergic acid diethylamide or (+)-amphetamine. In the study reported here, the (+)-MBDB cue generalized to MDMA and the parent drug, 3,4-methylenedioxyamphetamine. All three drugs exhibited a similar stereoselectivity, the (+)-isomer having potency greater than the (-)-isomer. By contrast, the hallucinogens, (+)-lysergic acid diethylamide, 2,5-dimethoxy-4-methylamphetamine and mescaline and the psychostimulants (+)-amphetamine and (+)-methamphetamine did not substitute for (+)-MBDB. Cocaine produced partial substitution. The results support the hypothesis that the primary behavioral activity of MDMA-like compounds is unlike that of hallucinogens and stimulants and may represent the effects of a novel drug class, given the name entactogens. Although the mechanism of action for the discriminative stimulus properties of MDMA-like compounds is not known, there is evidence that presynaptic serotonergic, but not dopaminergic, mechanisms are critical. Finally, 5,6-methylenedioxy-2-aminoindan a non-neurotoxic 3,4-methylenedioxyamphetamine rigid analog that was previously found to substitute for MDMA but not for (+)-lysergic acid diethylamide was found in the study described here to substitute completely for (+)-MBDB. The N-methyl derivative 5,6-methylenedioxy-2-methylminoindan produced similar results. The demonstration of entactogen-like discriminative stimulus properties, for drugs devoid of neuronal degenerative toxicity potential, serves as evidence of the independent mechanisms for these effects in rats.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1979813

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  12 in total

1.  Enantiomeric separations of illicit drugs and controlled substances using cyclofructan-based (LARIHC) and cyclobond I 2000 RSP HPLC chiral stationary phases.

Authors:  Nilusha L T Padivitage; Edra Dodbiba; Zachary S Breitbach; Daniel W Armstrong
Journal:  Drug Test Anal       Date:  2013-09-20       Impact factor: 3.345

2.  MDMA induces Per1, Per2 and c-fos gene expression in rat suprachiasmatic nuclei.

Authors:  Rowan P Ogeil; David J Kennaway; Mark D Salkeld; Shantha M W Rajaratnam; Jillian H Broadbear
Journal:  Psychopharmacology (Berl)       Date:  2011-10-26       Impact factor: 4.530

3.  Differences in the locomotor-activating effects of indirect serotonin agonists in habituated and non-habituated rats.

Authors:  Adam L Halberstadt; Mahálah R Buell; Diana L Price; Mark A Geyer
Journal:  Pharmacol Biochem Behav       Date:  2012-03-31       Impact factor: 3.533

4.  2-Aminoindan and its ring-substituted derivatives interact with plasma membrane monoamine transporters and α2-adrenergic receptors.

Authors:  Adam L Halberstadt; Simon D Brandt; Donna Walther; Michael H Baumann
Journal:  Psychopharmacology (Berl)       Date:  2019-03-23       Impact factor: 4.530

5.  Comparative potencies of 3,4-methylenedioxymethamphetamine (MDMA) analogues as inhibitors of [3H]noradrenaline and [3H]5-HT transport in mammalian cell lines.

Authors:  T Montgomery; C Buon; S Eibauer; P J Guiry; A K Keenan; G J McBean
Journal:  Br J Pharmacol       Date:  2007-09-24       Impact factor: 8.739

6.  Complex stimulus properties of LSD: a drug discrimination study with alpha 2-adrenoceptor agonists and antagonists.

Authors:  D Marona-Lewicka; D E Nichols
Journal:  Psychopharmacology (Berl)       Date:  1995-08       Impact factor: 4.530

Review 7.  (±)-MDMA and its enantiomers: potential therapeutic advantages of R(-)-MDMA.

Authors:  Elizabeth G Pitts; Daniel W Curry; Karly N Hampshire; Matthew B Young; Leonard L Howell
Journal:  Psychopharmacology (Berl)       Date:  2017-12-16       Impact factor: 4.530

Review 8.  Beyond ecstasy: Alternative entactogens to 3,4-methylenedioxymethamphetamine with potential applications in psychotherapy.

Authors:  Hans Emanuel Oeri
Journal:  J Psychopharmacol       Date:  2020-09-10       Impact factor: 4.153

9.  MDMA (3,4-Methylenedioxymethamphetamine) Analogues as Tools to Characterize MDMA-Like Effects: An Approach to Understand Entactogen Pharmacology.

Authors:  P Sáez-Briones; A Hernández
Journal:  Curr Neuropharmacol       Date:  2013-09       Impact factor: 7.363

Review 10.  Synthetic Aminoindanes: A Summary of Existing Knowledge.

Authors:  Nikola Pinterova; Rachel R Horsley; Tomas Palenicek
Journal:  Front Psychiatry       Date:  2017-11-17       Impact factor: 4.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.